Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid

Guarino, M P L; Carotti, S; Morini, S; Perrone, C; Behar, J; Altomare, A; AIIoni, R; Caviglia, R; Emerenziani, S; Rabitti, C; Cicala, M
December 2008
Gut;Dec2008, Vol. 57 Issue 12, p1740
Academic Journal
The article presents a study that evaluates the presence of macrophage infiltration and cyclooxygenase-2 (COX-2) expression in the gallbladder (GB) muscle layer. It also examines the effect of short-term ursodeoxycholic acid (UDCA) administration. Results show that an inflammatory macrophage infiltrate is present in the GB muscle layer of cholesterol gallstone patients. It was also found that UDCA decreases the presence of macrophages and improves GB muscle contraction.


Related Articles

  • Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study. Liberopoulos, E. N.; Florentin, M.; Elisaf, M. S.; Mikhailidis, D. P.; Tsiano, E. // Open Cardiovascular Medicine Journal;2010, Vol. 4, p120 

    Background: Most patients with primary biliary cirrhosis (PBC) are treated with ursodeoxycholic acid (UDCA); however, some do not respond fully. PBC is also associated with dyslipidemia, but a link with vascular risk has not been confirmed. Methods and Results: In this study we compared UDCA...

  • Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial Papatheodoridis, George V.; Hadziyannis, Emilia S.; Deutsch, Melanie; Hadziyannis, Stephanos J. // American Journal of Gastroenterology;Aug2002, Vol. 97 Issue 8, p2063 

    OBJECTIVES:The aim of this study was to evaluate whether ursodeoxycholic acid (UDCA) has any effect on the development of liver decompensation and on survival of patients with primary biliary cirrhosis (PBC).METHODS:A total of 86 patients with compensated PBC were randomly assigned to receive...

  • Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Fried, Ronald H.; Murakami, Carol S.; Fisher, Lloyd D.; Willson, Richard A.; Sullivan, Keith M.; McDonald, George B.; Fried, R H; Murakami, C S; Fisher, L D; Willson, R A; Sullivan, K M; McDonald, G B // Annals of Internal Medicine;4/15/92, Vol. 116 Issue 8, p624 

    Objective: To determine the safety and efficacy of ursodeoxycholic acid treatment in patients with chronic graft-versus-host disease (GVHD) of the liver.Design: Open-label study in which each patient served as his or her own control.Setting: Private...

  • Results of long-term ursodiol treatment for patients with primary biliary cirrhosis Jorgensen, Roberta; Angulo, Paul; Dickson, E. Rolland; Lindor, Keith D. // American Journal of Gastroenterology;Oct2002, Vol. 97 Issue 10, p2647 

    OBJECTIVE:When ursodeoxycholic acid (UDCA) is used for the treatment of primary biliary cirrhosis, it has been associated with biochemical improvement, histological stability, reduced risk of esophageal varices, and increased survival free of transplantation. There is limited information...

  • Calcification of radiolucent gall stones during treatment with ursodeoxycholic acid.  // British Medical Journal (Clinical Research Edition);9/5/1981, Vol. 283 Issue 6292, p645 

    Reports on the calcification of gall stones in six patients during treatment with ursodeoxycholic acid. Uses of both chenodeoxycholic and ursodeoxycholic acid; Description of ursodeoxycholic acid; Possibility of calcification during treatment with ursodeoxycholic acid.

  • Combined endoscopic and ursodeoxycholic acid treatment of biliary cast syndrome in a non-transplant patient. Katsinelos, Panagiotis; Kountouras, Jannis; Chatzimavroudis, Grigoris; Zavos, Christos; Pilpilidis, Ioannis; Paroutoglou, George; Llado, Laura // World Journal of Gastroenterology;9/7/2008, Vol. 14 Issue 33, p5223 

    A 76-year-old diabetic man underwent cholecystectomy for gangrenous calculous cholecystitis. His postoperative course was complicated by the development of Candida albicans esophagitis necessitating antifungal therapy, and total parenteral nutrition (TPN) for 15 d. Seven weeks after...

  • Ursodeoxycholic Acids: A Safe and Effective Agent for Dissolving Cholesterol Gallstones. Tint, G. Stephen; Salen, Gerald; Colalillo, Anthony; Graber, David; Verga, Diane; Speck, Jeffrey // Annals of Internal Medicine;Sep82, Vol. 97 Issue 3, p351 

    Presents a study which examined the effectiveness of using ursodeoxycholic acid in dissolving cholesterol gallstones and their effect on hepatic bile acid metabolism and liver function. Methods used in the study; Results.

  • Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases. Festi, Davide; Montagnani, Marco; Azzaroli, Francesco; Lodato, Francesca; Mazzella, Giuseppe; Roda, Aldo; Di Biase, Anna Rita; Roda, Enrico; Simoni, Patrizia; Colecchia, Antonio // Current Clinical Pharmacology;May2007, Vol. 2 Issue 2, p155 

    Ursodeoxycholic acid (UDCA), previously used for cholesterol gallstone dissolution, is currently considered the first choice therapy for many forms of cholestatic syndromes. Many mechanisms and sites of action have been proposed for UDCA, but definitive data are still missing regarding the key...

  • The Effect of Ursodeoxycholic Acid Therapy on Gallstone Formation in the Morbidly Obese during Rapid Weight Loss. Worobetz, L. J.; Inglis, F. G.; Shaffer, E. A. // American Journal of Gastroenterology;Oct1993, Vol. 88 Issue 10, p1705 

    Obesity is a significant risk factor for cholesterol gallstone formation, particularly when patients are morbidly obese and rapidly losing weight. Our objective, in a double-blind, placebo-driven trial of ursodeoxycholic acid, was to study the prevention of gallstone development in 29 morbidly...


Read the Article


Sign out of this library

Other Topics